When patients do develop diabetes, the newer drugs to treat diabetes are of special interest since these drugs have cardio-renal-metabolic effects (i.e., sodium-glucose cotransporter-2 (SGLT2) inhibitors or glucagon-like peptide 1 (GLP1) analogues) (29,30). This evidence concerns the gene SLC5A2 and diabetes mellitus.